Page 219 - FBL AR 2019-20

CORPORATE STATUTORY FINANCIAL
OVERVIEW STATEMENTS STATEMENTS

Notes to the Consolidated financial statements for the year ended March 31, 2020

45 Segment information: (contd.)
The segment information presented is in accordance with the accounting policies adopted for preparing the consolidated financial
statements of the Group. Segment revenues, expenses and results include inter-segment transfers.
A) The primary reporting of the Group has been performed on the basis of business segments, viz:
Property - Renting of properties
Chemicals/Bulk Drug- Manufacturing and selling of chemicals, primarily bulk drugs and enzymes.

Segments have been identified and reported based on the nature of the services, the risk and returns, the organisation structure and the
internal financial reporting systems.
( H in Lakhs )
2019-2020
2018-2019
Bulk Drug/Chemicals Property Total
a. Revenue
1 Segment revenue 27,550.83 1,963.05 29,513.88
38,925.52 1,953.41 40,878.93
Less : Inter-segment revenue - 230.33 230.33
- 411.89 411.89
Unallocated revenue (net) 1,243.67
1,236.52
2 Total 30,527.22
41,703.56
b. Result
1 Segment profit 5,533.83 563.10 6,096.93
15,149.14 582.97 15,732.11
2 Finance costs 1,914.04
2,065.31
3 Unallocable income/(expenditure) (net) 157.41
(1,534.91)
4 Inter segment results 1.71
738.72
5 Profit before tax 4,342.01
12,870.61
6 Tax expense
- current tax 338.88
3,195.65
- deferred tax credit (1,948.89)
(2,115.30)
7 Profit after tax 5,952.02
11,790.26
c. Other information
1. Segment assets 40,580.16 8,069.03 48,649.19
32,700.32 8,250.11 40,950.43
2 Unallocated corporate assets 12,718.26
14,174.28
3. Total assets 61,367.45
55,124.71
4. Segment liabilities 7,289.02 814.09 8,103.11
7,456.78 1,181.03 8,637.81
5. Unallocated corporate liabilities 22,319.56
21,430.30
6. Total liabilities 30,422.67
30,068.11
7. Cost incurred during the year to acquire
- segment tangible and intangible assets 6,846.93 - 6,846.93
3,481.17 45.88 3,527.05

217